Concepedia

Publication | Closed Access

NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma

DOI

120

Citations

44

References

2012

Year

Seth M. Pollack, Achim A. Jungbluth, Benjamin Hoch, Erik Farrar, Marie Bleakley, David J. Schneider, Elizabeth T. Loggers, Eve T. Rodler, Janet F. Eary, Ernest U. Conrad,
Cancer

Abstract

The current results establish NY-ESO-1 as an important target antigen for the treatment of patients with MRCL.

References

YearCitations

Page 1